GRI-0621, an experimental oral therapy for idiopathic pulmonary fibrosis (IPF), may stabilize lung function, according to an interim analysis of an ongoing Phase 2a study. Forced vital capacity (FVC), a measure of how much air a person can forcibly exhale, didn’t worsen during the first six weeks of the clinical trial (NCT06331624). The company recently […] The post Experimental oral therapy GRI-0621 may stabilize lung function in IPF appeared first on Pulmonary Fibrosis News.
